Background To better understand the profile of individuals with severe coronavirus disease 2019 (COVID-19), we characterised individuals hospitalised with COVID-19 and compared them to individuals previously hospitalised with influenza. and hypertensive disorder from 22% to 70% across INK 128 price data sources, while between 9% and 39% were taking drugs acting on the renin-angiotensin system in the 30 days prior to their hospitalisation. Compared to 52,422 individuals hospitalised with influenza, patients admitted with COVID-19 were more likely male, younger, MPS1 and, in america, got fewer comorbidities and lower medicine use. Conclusions Prices of medicine and comorbidities make use of are great among people hospitalised with COVID-19. However, COVID-19 sufferers will be male and appearance to INK 128 price be young and, in america, healthier than those typically admitted with influenza generally. Launch The ongoing coronavirus disease 2019 (COVID-19) pandemic is certainly placing an enormous strain on wellness systems world-wide. While several studies have supplied information in the scientific features of individuals getting hospitalised with COVID-19,[1C3] significant uncertainty across the prevalence of comorbidities and prior medicine make use of among this inhabitants remains. Moreover, it isn’t known whether those hospitalised with COVID-19 will vary to people hospitalised during previous influenza periods systematically. Providing such details would help inform the existing response to COVID-19. COVID-19 stocks commonalities with influenza towards the level that both trigger respiratory disease that may differ markedly in its intensity and present with an identical constellation of symptoms, including fever, coughing, myalgia, INK 128 price fatigue and malaise, and dyspnea. Early reviews do, however, indicate the fact that percentage of serious mortality and attacks price INK 128 price are higher for COVID-19.[4] Old age and a variety of underlying health issues, such as immune system deficiency, coronary disease, chronic lung disease, neuromuscular disease, neurological disease, chronic renal disease, and metabolic illnesses, have been connected with an increased threat of severe influenza and associated mortality.[5] While age is apparently an obvious risk factor for severe COVID-19,[4] other associations aren’t yet well understood. Evaluations with COVID-19 are additional complicated with the heterogeneity in influenza itself, with different strains leading to different scientific presentations and linked dangers. Those hospitalised using the A(H1N1)pdm09 subtype from the influenza A pathogen during the linked influenza pandemic in ’09 2009 were, for instance, generally young and with fewer comorbidities than those from preceding influenza periods.[6] Routinely-collected healthcare data can improve our knowledge of the features of individuals hospitalised with COVID-19, with years of prior clinical observations recorded. In this study, our first aim was to characterise the demographics and medical histories of individuals hospitalised with COVID-19 across multiple institutions in two countries. Subsequently, we aimed to compare the characteristics of those hospitalised with COVID-19 with those of individuals hospitalised with influenza in previous years. Methods Study design This is a cohort study based on routinely-collected electronic health records (EHRs) and claims data from the US and South Korea. The data sources used were mapped to the Observational Medical Outcomes Partnership (OMOP) Common Data Model (CDM).[7] The open-science Observational Health Data Sciences and Informatics (OHDSI) network maintains the OMOP CDM, and its members have developed a wide range of tools to facilitate analyses of such mapped data.[8] Two particular benefits of this approach were that contributing centres did not need to share patient-level data and common analytical code could be applied across databases. Data INK 128 price sources Data from the US and South Korea underpinned the study. EHR data from the US came from the Columbia University Irving Medical Center (CUIMC), covering NewYork-Presbyterian Hospital/Columbia University Irving Medical.